RecruitingPhase IIIFemale onlyEN originalOvarian cancerMetastatic / advanced

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

⚠️

This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.

About the trial

The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice of chemotherapy and bevacizumab in women diagnosed with platinum-resistant/refractory ovarian cancer (includes fallopian tube cancer and primary peritoneal cancer). This Phase III trial builds on the efficacy and safety data reported in the previous Phase II VIRO-15 trial with promising objective response rate and progression-free survival observed in heavily pre-treated patients with platinum-resistant/refractory ovarian cancer. The phase II results also showed that the intra-peritoneal route of delivery was efficient in generating tumor cell killing and immune activation, and led to clinical reversal of platinum-resistance or refractoriness in this difficult-to-treat patient population.

Original English text from ClinicalTrials.gov

Who can (and can't) join

✓ Qualifies

  • Potwierdzony histologicznie rak jajnika, jajowodu lub osierdzia pierwotnego
  • Wysoko złośliwy typ raka (serous, endometrioid lub jasnokomórkowy)
  • Ogólny stan zdrowia pozwalający na leczenie (ECOG 0-1)
  • Spodziewana długość życia co najmniej 6 miesięcy
  • Co najmniej 3 wcześniejsze leczenia zawierające chemioterapię
  • Rak oporny na platynę (powrót choroby 1-6 miesięcy po ostatniej platynie) lub nieodpowiadający (powrót w ciągu 1 miesiąca)
  • Poprzednie leczenie bevacizumabem
  • Zmierzone zmiany nowotworowe widoczne w badaniach obrazowych i rak w obrębie brzuszenia

✗ Disqualifies

  • Inne typy raka jajnika (śluzowy, niskogradusowy, drobnokomórkowy)
  • Niedrożność jelit w ciągu ostatnich 3 miesięcy
  • Aktywna infekcja układu moczowego, zapalenie płuc lub inne infekcje

Simplified criteria — AI translation

Trial details

Minimum age
18 Years
Last updated (source)
July 10, 2026
Sex
Female only

Therapies / drugs in trial

Locations (32)

The University of South Alabama, Mitchell Cancer Institute

Mobile, United States

University of Arizona Cancer Center

Tucson, United States

City of Hope

Duarte, United States

UC San Diego Health - Moores Cancer Center

La Jolla, United States

Hoag Gynecologic Oncology

Newport Beach, United States

UCI Health Chao Family Comprehensive Cancer Center

Orange, United States

AdventHealth Cancer Institute

Orlando, United States

Sarasota Memorial Healthcare System

Sarasota, United States

Women's Cancer Associates with Women's Care Florida

St. Petersburg, United States

Emory University

Atlanta, United States

Indiana University Simon Comprehensive Cancer Center

Indianapolis, United States

Holy Cross Hospital

Silver Spring, United States

University of Michigan

Ann Arbor, United States

Karmanos Cancer Institute

Detroit, United States

Washington University School of Medicine

St Louis, United States

Mercy Hospital St. Louis

St Louis, United States

Women's Cancer Center of Nevada

Las Vegas, United States

Center of Hope

Reno, United States

Stony Brook Cancer Center

Stony Brook, United States

Levine Cancer Institute

Charlotte, United States

East Carolina University

Greenville, United States

Cleveland Clinic

Cleveland, United States

OhioHealth Research Institute

Columbus, United States

Kettering Health

Kettering, United States

ProMedica Flower Hospital

Sylvania, United States

Oklahoma University Health Stephenson Cancer Center

Oklahoma City, United States

AHN West Penn Hospital

Pittsburgh, United States

Hollings Cancer Center

Charleston, United States

Erlanger Health, Inc.

Chattanooga, United States

Baylor College of Medicine

Houston, United States

University of Texas Science Center at Houston, McGovern Medical School

Houston, United States

Providence Sacred Heart Medical Center & Children's Hospital

Spokane, United States

Trial contact

Jennifer Pierce, MD

PRINCIPAL_INVESTIGATOR

Setsuko K. Chambers, MD

PRINCIPAL_INVESTIGATOR

Edward Wang, MD, PhD

Edward Wang, MD, PhD

PRINCIPAL_INVESTIGATOR

Michael McHale, MD

PRINCIPAL_INVESTIGATOR

Ramez Eskander, MD

SUB_INVESTIGATOR

Alberto Mendivil, MD

PRINCIPAL_INVESTIGATOR

Krishnansu S. Tewari, MD

Krishnansu S. Tewari, MD

PRINCIPAL_INVESTIGATOR

Robert W Holloway, MD

PRINCIPAL_INVESTIGATOR

Sarasota Memorial Healthcare System

Beverly Long, MD

PRINCIPAL_INVESTIGATOR

Megan Indermaur, MD

PRINCIPAL_INVESTIGATOR

Jennifer Scalici, MD

PRINCIPAL_INVESTIGATOR

Jessica E. Parker, MD

PRINCIPAL_INVESTIGATOR

Lyudmila Igorevna Kalnitskaya, MBA, MS

Frederick D Min, MD

PRINCIPAL_INVESTIGATOR

Jasmine Ebott, MD

SUB_INVESTIGATOR

Jean Siedel, MD

PRINCIPAL_INVESTIGATOR

Robert Morris, MD

PRINCIPAL_INVESTIGATOR

Premal Thaker, MD

PRINCIPAL_INVESTIGATOR

Madhavi Manyam, MD

PRINCIPAL_INVESTIGATOR

Nicola M. Spirtos, MD

PRINCIPAL_INVESTIGATOR

Peter Lim, MD

PRINCIPAL_INVESTIGATOR

Gabrielle Gossner, MD

PRINCIPAL_INVESTIGATOR

Erin K Crane, MD

PRINCIPAL_INVESTIGATOR

Grainger Lanneau, MD

PRINCIPAL_INVESTIGATOR

Peter Rose, MD

PRINCIPAL_INVESTIGATOR

Aine Clements, MD

PRINCIPAL_INVESTIGATOR

Thomas J. Reid, MD

PRINCIPAL_INVESTIGATOR

Adam Walter, MD

PRINCIPAL_INVESTIGATOR

Debra Richardson, MD

PRINCIPAL_INVESTIGATOR

Sarah Crafton, MD

PRINCIPAL_INVESTIGATOR

Brian Orr, MD

PRINCIPAL_INVESTIGATOR

Stephen DePasquale, MD

PRINCIPAL_INVESTIGATOR

Jan Sunde, MD

PRINCIPAL_INVESTIGATOR

Joseph Lucci, III, MD

PRINCIPAL_INVESTIGATOR

Melanie Bergman, MD

PRINCIPAL_INVESTIGATOR

Contact information from ClinicalTrials.gov. Contact in English.

Share this trial

Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/11/2026.

You can help another person

We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.